KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Shares Outstanding (Diluted Average) (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Shares Outstanding (Diluted Average) for 17 consecutive years, with $107.7 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding (Diluted Average) fell 3.15% year-over-year to $107.7 million; the TTM value through Mar 2026 reached $107.7 million, down 3.15%, while the annual FY2025 figure was $108.6 million, 5.65% down from the prior year.
  • Shares Outstanding (Diluted Average) hit $107.7 million in Q1 2026 for Regeneron Pharmaceuticals, down from $108.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $115.6 million in Q3 2024 and bottomed at $107.7 million in Q1 2026.
  • Average Shares Outstanding (Diluted Average) over 5 years is $112.7 million, with a median of $113.7 million recorded in 2023.
  • Year-over-year, Shares Outstanding (Diluted Average) rose 2.89% in 2022 and then fell 5.8% in 2025.
  • Regeneron Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $113.5 million in 2022, then grew by 0.18% to $113.7 million in 2023, then increased by 1.23% to $115.1 million in 2024, then fell by 5.65% to $108.6 million in 2025, then dropped by 0.83% to $107.7 million in 2026.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $107.7 million, $108.6 million, and $108.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.